Abstract Vertebral collapse is a common fracture associated with osteoporosis. Subsequent pain may be severe and often requires medications and bed rest. Several studies have suggested the use of calcitonin for the treatment of fracture pain. We sought to determine the analgesic efficacy of calcitonin for acute and chronic pain of osteoporotic vertebral compression fractures (OVCF). We searched for randomized, placebo, and controlled trials that evaluated the analgesic efficacy of calcitonin for pain attributable to OVCFs. We performed meta-analyses to calculate standardized mean differences (SMDs) using a fixed or random effects model. The combined results from 13 trials (n=589) determined that calcitonin significantly reduced the severity of acute pain in recent OVCFs. Pain at rest was reduced by week 1 [mean difference (MD)=−3.39, 95% confidence interval (CI)=−4.02 to −2.76), with continued improvement through 4 weeks. At week 4, the difference in pain scores with mobility was even greater (SMD=−5.99, 95% CI=−6.78 to −5.19). For patients with chronic pain, there was no statistical difference between groups while at rest; there was a small, statistically significant difference between groups while mobile at 6 months (SMD=0.49, 95% CI=−0.85 to −0.13, p=0.008). Side effects were mild, with enteric disturbances and flushing reported most frequently. Although calcitonin has proven efficacy in the management of acute back pain associated with a recent OVCF, there is no convincing evidence to support the use of calcitonin for chronic pain associated with older fractures of the same origin.
Introduction

Background
Osteoporosis is a serious public health problem for older adults, with an estimated 1.4 million Canadians and 10 million Americans affected [1, 2] . The epidemiological and clinical importance of osteoporosis lies in the fractures that are associated with the disease, with over 70% of all fractures in older adults being attributed to osteoporosis [3] . Although osteoporotic fractures may occur at multiple sites, vertebral collapse is one of the most common; in developed countries like Canada, the lifetime risk of an osteoporotic vertebral compression fracture (OVCF) is one in four among women and one in eight among men, and increases in prevalence with age in both sexes [2] . Not only is the condition common, it is also costly; in 2005, in the USA alone, patients sustained more than 2 million fractures, costing the health care system nearly US $17 billion [4] .
Description of the condition
An OVCF can be diagnosed radiographically or as a symptomatic clinical event whereby patients present with back pain typically of sudden onset associated with a relatively atraumatic event such as bending or coughing [5] . When an acute OVCF occurs, the pain may be so devastating and disabling that hospital admission is required; length of stay for such fractures may be as long as 10 to 14 days [6] [7] [8] . On the other hand, OVCFs may be associated with mild back pain and stiffness, and the diagnosis of a fracture often goes unnoticed [9] . Although many patients with OVCF experience a predictable improvement in pain over 6-8 weeks [7] , some patients experience persistent pain and disability. Multiple OVCFs can lead to a gradual but noticeable loss of vertebral height, leading to progressive dorsal kyphosis. Chronic back pain may result from the associated deformity, joint incongruity, and tension on muscles and tendons; consequently, a significant impairment in spinal range of motion and physical function, including mobility, and lower overall quality of life may be reported [10, 11] .
Description of the intervention
The pain of an OVCF is often treated with standard analgesics, although these commonly used analgesics (e.g., acetaminophen with codeine) and non-steroidal anti-inflammatory drugs are not always helpful or appropriate in the older adult population. Sedative-hypnotic medications and narcotics are frequently prescribed for patients with fractures; however, these agents are often associated with important and dangerous side effects [12] .
A number of studies have suggested the use of calcitonin as an initial and adjunctive treatment for acute, severe, and unrelenting back pain secondary to fracture as calcitonin exhibits known analgesic properties [13] [14] [15] . Some studies have suggested that calcitonin may also be useful in the treatment of chronic back pain related to a more remote OVCF [16, 17] . Calcitonin is a 32-amino acid polypeptide produced and secreted by the thyroid gland of mammals and is available as a nasal spray [intranasal (IN)], an injection [intramuscular (IM) or subcutaneous (SQ)], and as a rectal suppository [18] . Although a number of mechanisms have been suggested, there are two most likely hypotheses explaining the analgesic mechanism of calcitonin: a direct central nervous system action involving calcitonin-binding receptors and an increase in plasma β-endorphin levels [19, 20] .
Relevance of systematic review and meta-analysis
The original Cochrane style systematic review on this topic [21] was published in 2005 and focused solely on the acute pain of recent OVCFs. This review not only provides an update to the previous results but also adds an additional dimension related to the use of calcitonin for chronic pain of more remote OVCFs. Given the morbidity associated with these types of fractures, and the frequent necessity of providing analgesia for patients with acute and chronic fracture pain, it is important to determine the effectiveness of calcitonin for both indications. Therefore, we conducted a formal Cochrane style systematic review and metaanalysis of controlled trials to examine the analgesic efficacy of participants receiving calcitonin (any route) compared with a control group receiving either a placebo, no intervention, or "usual care" in older adults with acute (onset <10 days) or chronic pain (>3 months) attributed to a recent or remote OVCF.
Objectives
The objectives of this systematic review were:
1. To assess the analgesic effects of calcitonin (any route), as judged by a quantitative pain scale, in older adults with acute or chronic pain of a recent or remote OVCF, 2. To assess concomitant consumption of other analgesic drugs, side effects, and withdrawals from studies (based on route of calcitonin administration), and 3. To update the previous systematic review with the latest evidence.
Methods
We followed the procedures for conducting systematic reviews and meta-analysis as outlined by the Cochrane Collaboration [22] and the reporting guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [23] .
Criteria for considering studies for this review
Types of studies
We planned to include a broad range of controlled comparison studies: randomized controlled trials (RCTs), controlled trials, and controlled before and after studies. As there were few such experimental studies, we planned to include observational studies if they included a control group, to compare outcomes. The studies needed to compare the analgesic effect of calcitonin to either placebo, to no intervention, or to "usual care," in any setting (including acute care hospital, rehabilitation facility, nursing homes, and the community), published in any language, and for which adequate information was provided or could be obtained from the primary researchers. Retrospective studies and studies in which there was no comparison group were excluded from the review.
Types of participants
To be eligible for inclusion, studies needed to involve older adults (aged 60 years and older) of either sex who suffered from acute (onset <10 days) or chronic back pain (>3 months) associated with a clinician diagnosis of an OVCF (by radiograph or clinical presentation) who received calcitonin (any route and any dose) or placebo or "usual care." Patients may have resided in any health care facility (acute or rehabilitation care), a community care setting (nursing home or assisted living), or in their own homes.
Types of interventions
Studies were included if they evaluated the effectiveness of calcitonin given by any route to achieve analgesia. Comparative treatments included placebo, usual treatment, or other known analgesics. Trials that compared different doses or routes of calcitonin, with no inactive comparator group, were excluded.
Types of outcome measures
All clinical outcomes were considered; however, the primary outcome of interest was the analgesic efficacy of calcitonin as judged by a quantitative pain scale [e.g., visual analogue scale (VAS)]. Pain scores ideally were assessed with patients at rest, sitting, standing, and walking in order to describe not only pain relief but also the length of time to mobilization. The concomitant consumption of other analgesic drugs, side effects, and withdrawals from studies (based on route of calcitonin administration) were also examined. A priori, we planned subgroup analyses based on: the sex and age of participants, route of calcitonin administration, and acute vs. chronic pain. 
Data collection and analysis
Selection of studies
One of the study investigators (JKS) performed the initial search of all databases to identify potentially relevant citations. Where it was not possible to accept or reject the study, the full text of the citation was obtained for further evaluation. Following the screening of titles and abstracts, the full texts of potential articles were retrieved (and translated into English where required) and assessed independently by two of the study investigators (JKS, CNC). If any differences in opinion occurred, they were resolved by consensus with a third reviewer.
Data extraction and management
Data were independently extracted by one unmasked reviewer (JKS) using a standardized electronic data collection form (based on the Cochrane Collaboration checklist of items to consider in data collection) [24] . When raw data were not provided, the data were extracted from figures; where necessary, we attempted to seek additional information from the first or corresponding authors of the included studies via electronic mail. The following information was obtained for each study (where possible): source, eligibility, methods, participants, interventions, outcomes, results, and funding sources. When possible, data from intention-to-treat (ITT) analysis were extracted; otherwise, we used the data presented on available cases.
Assessment of risk of bias in included studies
After identification of articles meeting the inclusion criteria, two review authors (CNC, JH) independently assessed the methodological quality of studies according to the "risk of bias approach" of the Cochrane Collaboration [25] . Specifically, we used the following six separate criteria: These criteria, which reflect the internal validity of the trials, were assessed for each of the included studies and were presented in a two-part "risk of bias" table. Within each entry, the first part of the tool involves describing what was reported in the study. The second part of the tool involves assigning a judgment relating to the risk of bias for that entry with each criterion scored as "yes," "no," or "unclear." This was achieved by answering a prespecified question about the adequacy of the study in relation to the entry such that a judgment of "yes" indicates low risk of bias, "no" indicates high risk of bias, and "unclear" indicates unclear or unknown risk of bias (see Appendix 2: The Cochrane Collaborations Risk of Bias Tool). Studies that met all criteria, or all but one criteria, were considered to be of high quality [25] . In the case of disagreement between reviewers, differences were to be resolved by discussion until consensus was achieved.
Measurement of treatment effect
A priori, we planned that for continuous data reported as means with standard deviations (SD), the effect measures would be generated as a mean difference (MD) or as a standardized mean difference (SMD) with 95% confidence intervals (CI). Specifically, for data measured on the same scale (i.e., a 10-cm or 100-mm VAS), a MD and the 95% CIs were calculated. When different methods of pain measures were used (i.e., a 10-cm VAS and a five-point pain scale), we calculated the SMD and 95% CIs to pool the results across trials. The SMD is used as a summary statistic in meta-analyses when the studies all assess the same outcome but measure it in a variety of ways (for example, all studies measure pain but they use different scales). In this circumstance, it is necessary to standardize the results of the studies to a uniform scale before they can be combined. The SMD expresses the size of the intervention effect in each study relative to the variability observed in that study [26] .
Where appropriate, data for dichotomous outcomes were pooled using the Mantel-Haenszel approach to calculate a risk ratio (RR) with 95% CIs. Numbers needed to treat for an additional harmful outcome (NNTH) were calculated for the reported side effects using the pooled RR and the assumed control risk (ACR) using the method described in Chapter 12.5.4.2 of the Cochrane Handbook for Systematic Reviews of Interventions [27] .
Dealing with missing data
As missing data (statistics) were evident in many of the included trials, we attempted to contact the trial investigators at least twice. In all but three cases, there were no responses; therefore, the available data were extracted from the published report and missing data were imputed. When only p values or the standard error of the mean (SEM) were reported, SDs were calculated according to the approach described in Chapter 7.7.3 of the Cochrane Handbook for Systematic Reviews of Interventions for handling missing data [24] . Sensitivity analyses were performed to check the effect of imputation.
Assessment of heterogeneity and reporting bias
Heterogeneity between studies was described nonstatistically and statistical heterogeneity between studies was examined visually using an I 2 statistic and a chisquared test (a chi-squared p value of <0.1 or an I 2 value equal to or >50% was considered indicative of possible heterogeneity). Deeks and colleagues (for the Cochrane Collaboration) [27] Possible sources of heterogeneity were assessed by sensitivity analyses. Heterogeneity was also examined qualitatively and described in Table 1 (characteristics of included studies) and Table 2 (risk of bias in included studies). We planned to explore publication bias and other potential reporting biases using funnel plots [28] .
Data synthesis
Meta-analyses were performed using the Cochrane Collaboration software program Review Manager (Rev Man), version 5 [29] . Meta-analyses methods were selected based on study heterogeneity and the number of trials included in the analyses. When the I 2 statistic •Pain intensity using a 10-point numerical scale (0 = no pain and 10 = maximum pain)
•Functional capacity: ability to dress, walking capacity, and ability to climb or descendstairs (0 = no difficulty and 3 = maximum difficulty). The final value is in the sum of the values obtained in each of the items surveyed, with a maximum possible value of 9
•Side effects •Amount of analgesics used DB double blind, DP double placebo, ITT intention to treat, IM intramuscular, OP osteoporosis, PC placebo controlled, RCT randomized controlled trial, SD standard deviation, SQ subcutaneous, VAS visual analogue scale was >75%, we considered it substantial heterogeneity and pooled the study results using a random effects (RE) model. If no significant statistical heterogeneity was detected, or there were a small number of trials included in the analysis (three or fewer), we used a fixed-effect model [27] . Continuous data were entered into Rev Man in such a way that, when analyzing the forest plot graphs, the area to the left of midline (<0) indicated a positive effect of the treatment drug calcitonin. When interpreting results of the forest plots for dichotomous data, the area to the right side of the forest plot graph (>1) favored the control group.
Subgroup analysis and investigation of heterogeneity
A priori, we planned to explore and address possible clinical heterogeneity as well as to investigate the effect modification of participants and treatments by performing subgroup analyses on the route of calcitonin administration (IN, IM/SQ, or rectal), the synthetic derivative of calcitonin (salmon vs. eel. vs. human), and the efficacy of calcitonin for both acute (<10 days) and chronic pain (>3 months). For studies examining acute fracture pain, we defined five periods for which we tried to extract data and analyze study findings: baseline, week 1, week 2, week 3, and week 4. For studies examining chronic pain of remote fractures, we aimed to extract data and analyze study findings at baseline and then again at 1, 3, 6, 9, and 12 months.
Sensitivity analysis
We performed sensitivity analyses by examining the results of the meta-analysis under different assumptions and checked for the robustness of the observed findings. A priori, the following sensitivity analyses were planned:
1. For trials in which the SD was not reported and therefore had to be imputed, do the results of the pooled analysis change if these are excluded from the results? 2. By limiting included studies in the analyses to those with the highest methodological quality, do the results change?
Results Figure 1 outlines the study selection process. We initially identified 308 citations, of which 55 were potentially relevant studies. Of the 55 full text articles retrieved for closer examination, 42 were excluded for the following reasons: 11 included patients with no vertebral fracture [20, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , nine had insufficient data and we were unable to locate study authors [40] [41] [42] [43] [44] [45] [46] [47] [48] , six had a diagnosis other than osteoporosis [49] [50] [51] [52] [53] [54] , six lacked an inactive (or no drug) comparison group [55] [56] [57] [58] [59] [60] , the library was unable to locate three full text articles and we were unable to locate the study authors [61] [62] [63] , three were review articles [64] [65] [66] , two were duplicate publications from a single study reporting the same results [67, 68] , one was a case report [69] , and one included participants with multiple fracture sites [70] . Thirteen trials were identified which met the inclusion criteria for the systematic review; six were studies focused on the acute pain of recent fractures [71] [72] [73] [74] [75] [76] and seven were chronic pain studies [16, 17, [77] [78] [79] [80] [81] . We were unable to include three of the studies in the meta-analysis due to insufficient data (means and SD of pain score not provided) [17, 76, 78] . Therefore, 10 studies were included in the quantitative synthesis.
Characteristics of included studies
Participants
The 13 included studies involved 589 participants, all of whom contributed data to the withdrawal and side effect analyses; 10 studies with 467 participants provided data in the analgesic efficacy (pain scale) meta-analyses. Recruitment procedures were predominantly not defined or were poorly reported, with little detail provided; however, it appeared that convenience samples predominated. See characteristics of included studies in Table 1 .
Design
All studies included were randomized, prospective controlled trials; most of the trials described withdrawals and side effects. Three of the trials were randomized and doubleblinded [73] [74] [75] with the use of sealed, serially numbered opaque envelopes. As patients met the appropriate criteria and became eligible for entry into trial, the next in a pile of sealed envelopes was opened. Inside was a card that indicated whether the patient was assigned to the treatment or control group. The ordering of the cards within the envelopes was determined from a table of random numbers. An additional three of the studies utilized "block randomization" [16, 17, 78] : One of the trials was randomized according to a "randomization list" [71] , one randomized participants according to a table of randomized numbers [76] , and the remaining five studies simply stated that they randomized participants, but did not describe their methods [17, 72, 77, 79, 80] .
Setting
A single research group in Greece conducted three of the studies [73] [74] [75] and three of the studies were conducted in Italy [16, 77, 80] ; the remaining studies were conducted in Austria [79] , Brazil [81] , Chile [71] , France [72] , Greece [78] , Hong Kong [76] , and Sweden [17] . Four of the studies were conducted using hospitalized patients [73] [74] [75] [76] ; the remaining nine studies included participants from the community. Only one of the studies was a multicentre trial [16] .
Interventions
The intervention groups received calcitonin by various routes: either nasal spray (seven studies) [16, 74, [76] [77] [78] [79] [80] , injection (six studies) [17, 71, 72, 75, 80, 81] , or by rectal suppository (one study) [73] . Ten studies included an identical placebo group [17, 71-77, 80, 81] , and three studies included a comparison group where the participants received various doses of calcium and vitamin D, but did not receive a placebo [16, 78, 79] .
Outcomes
Of the 13 studies included, six involved patients with acute back pain (<10 days) attributed to a recent OVCF [71] [72] [73] [74] [75] [76] and seven included patients with chronic back pain (>3 months) attributed to a remote OVCF [16, 17, [77] [78] [79] [80] [81] . Although all studies analyzed pain scores, three studies presented their data in such a way that the results could not be included in the meta-analysis [17, 76, 78] . The timing of outcome measures was variable, ranging from 14 to 28 days for measures of acute pain and from 1 week to 1 year for measures of chronic pain. Various pain scales were used in the trials: a 10-cm or 100-mm VAS predominated (0 = no pain to 10 = intolerable pain) [17, [72] [73] [74] [75] [76] [78] [79] [80] [81] , followed by studies utilizing a descriptive four-point scale (0/1 = normal to 4 = movement impossible/very severe) [16, 77] and a five-point scale (0 = none to 5 = pain in bed without moving) [71] . All studies provided information on withdrawals and side effects experienced by both treatment and comparison groups. With the exception of the participants in one of the studies [80] , all participants were allowed concomitant analgesics, but only a few of the studies provided data on their usage.
Quality assessment-risk of bias in included studies
The methodological quality of trials varied significantly (see summary results presented in Table 2 ). The initial agreement of the reviewers on the total assessment of risk of bias was 97% (74 of 76 items). Any initial disagreements were solved by consensus. An adequate method of sequence generation was reported in five trials [73] [74] [75] [76] 78] and an adequate method for allocation concealment in three trials [73] [74] [75] . Patients were blinded in all but three studies [16, 78, 79] , and attrition was low or adequately accounted for in all but one study [72] . Three studies met all formal quality criteria [73] [74] [75] , one study met four criteria [80] , and four studies met three of the quality requirements [17, 71, 76, 77] . A priori, publication bias was to be tested using the funnel plot visually and quantitatively, that is, the rank correlation test [82] and the graphical test with or without heterogeneity [28] . However, given the small number of trials included in the review, the interpretation of these plots must be undertaken with caution and are not included here.
Effects of interventions: analgesic efficacy of calcitonin
The statistical analysis (related to the analgesic efficacy of calcitonin) included data from 10 trials with 467 participants [420 women (90.0%) and 47 men (10.0%)]. The mean ages of participants (at entry) in the treatment and control groups were 67.4 and 66.9 years, respectively. The studies were analyzed and the results pooled for two separate groups: those including participants with (1) acute back pain (<10 days duration) [71] [72] [73] [74] [75] attributed to a recent OVCF and (2) chronic back pain (>3 months duration) [16, 77, [79] [80] [81] attributed to a remote OVCF.
Acute back pain
Five studies included participants with acute back pain of a recent OVCF [260 participants, 213 females (82%) and 47 males (18%)]. The mean age of participants was 70.8 years in the calcitonin group and 71.2 years in the control group. Of the five studies, three used a 10-cm VAS [73] [74] [75] , one used a 100-mm VAS [72] , and the final used a descriptive five-point scale as a subjective measure of participant self-reported pain [71] . In three of the trials, VAS measures were initiated on day 0 (baseline) and then again at least weekly for up to 4 weeks during bed rest, sitting, standing, and walking [73] [74] [75] . Another study measured pain scores with patients only at rest and assessed pain on a 100-mm VAS at baseline, week 2, and again at week 4 [72] . The final study measured pain by assessing patients' activity/mobility using a fivepoint scale; the measurements were assessed at day 0 (baseline) and days 3, 7, 14, 21, and 28 [71] .
As determined a priori, two subgroups were created: (1) pain assessed at rest and (2) pain assessed with mobility. Because there were too few trials and insufficient data, we were unable to carry out subgroup analysis based on sex and age of participants or the route of calcitonin administration. Within the subgroups, analyses were done at baseline and then weeks 1 to 4. All five of the studies employed the use of salmon calcitonin; therefore, sensitivity analysis related to calcitonin derivative was not necessary. Overall, a small number of trials were included and the pooled analyses displayed statistical heterogeneity; therefore, the estimates were based on the RE model [27] .
Acute pain at rest Four trials studied participants while at rest or stationary [72] [73] [74] [75] ; baseline results of the population revealed a relatively homogeneous sample with moderate to severe pain (VAS ranged from a mean score of 6.1 to 10 out of 10) with no statistical difference between the groups (p=0.56). Following 1 week of treatment, there was a statistically significant improvement in the resting pain score for patients receiving calcitonin (MD=−3.39, 95% CI=−4.02 to −2.76) compared with the control group. The chi-square test of heterogeneity was not significant for the RE pooled result (I 2 =24%, p=0.27). This result was not significantly different from the results seen at 2, 3, and 4 weeks with the subjects at rest (forest plot of the results presented in Fig. 2 ).
Significant heterogeneity (I 2 >90%) of the RE pooled results (with participants at rest) was demonstrated in weeks 2 and 4. Sensitivity analyses, based on the imputing of SDs where means were provided (but no SD) [72, 73] , were non-significant as the direction and magnitude of treatment effect did not change. For example, the VAS (pain scores) measured at rest on week 2, excluding the studies with no SD provided, showed a homogeneous sample (I 2 =0%) with a MD of −4.65 (95% CI=−5.18 to −4.12) as compared with a MD of −3.75 (95% CI=−5.52 to −1.98) when including all four studies.
Acute pain with mobility Four trials studied participants while mobile [71, [73] [74] [75] ; baseline results of the population revealed a homogeneous sample (I 2 =18%, p=0.30) with no statistical difference between the groups (p=0.46). By week 1, there was a significant improvement in the RE pooled score (SMD=−2.60, 95% CI=−4.07 to −1.13) compared with the control group. This result was not significantly different from results seen at weeks 2, 3, and 4 (forest plot of the results presented in Fig. 3 ). The only comparisons demonstrating significant heterogeneity in their RE pooled results were at weeks 1 and 2 (I 2 >90%). Sensitivity analyses, based on the imputing of SDs into the studies where means were provided (but no SD) [71, 73] , were non-significant as the magnitude of the treatment effect did not change. For example, the pain scores with mobility at week 2, excluding the studies where the SD was imputed, showed a SMD of −4.35 (95% CI=−6.23 to −2.47) as compared with a SMD of −3.75 (95% CI=−5.52 to −1.98).
Chronic back pain
The five studies including participants with chronic back pain of a remote OVCF included 207 participants (100% women). The mean age of participants was 64 years in the calcitonin group and 63.1 years in the control group. Of the five studies, two used a 10-cm VAS [79, 81] , one used a 100-mm VAS [80] , and two used descriptive four-point scales as a 
Total (95% CI)
Heterogeneity: Tau² = 6.41; Chi² = 1092.27, df = 15 (P < 0.00001); I² = 99% Test for overall effect: Z = 4.39 (P < 0.0001) Fig. 2 Acute pain measured at rest. Forest plot of all included studies reporting the acute pain of a recent OVCF, measured at rest on day 0 (baseline) and weeks 1 to 4. Horizontal lines, 95% CIs of each study; green squares, MDs of each individual study (the size represents the weight that the study was given in the meta-analysis); diamond, the summary estimate; solid vertical line, null value. MDs less than zero indicate a treatment benefit subjective measure of participant self-reported pain [16, 77] . All of the trials initiated pain score measurements at baseline (day 0), one of the trials followed patients closely for 6 months [81] , and two of the trials followed patients for up to 1 year [16, 79] . The remaining two trials employed short-term measures: One assessed pain scores weekly for up to 4 weeks [80] and the other assessed patients at 2 weeks and then monthly for 3 months [77] .
As determined a priori, two subgroups were created: (1) pain assessed at rest and (2) pain assessed with mobility.
Because there were too few trials and insufficient data, we were unable to carry out subgroup analysis based on sex and age of participants or the route of calcitonin administration. For pain assessed at rest, pooled analyses were only possible at baseline and then at 3 months. For the group assessed while mobile, pooled analyses were possible at baseline, weekly until week 4, and then again at 3 and 6 months. Overall, there were a small number of trials included and the pooled analyses displayed statistical heterogeneity; therefore, the estimates were based on the RE model [27] . (the size represents the weight that the study was given in the metaanalysis); diamond, the summary estimate; solid vertical line, null value. SMDs less than zero indicate a treatment benefit Chronic pain at rest Two of the five studies included assessments while patients were at rest [16, 77] . The baseline result of this chronic back pain population revealed a homogeneous sample (I 2 =0%, p =0.36) with slight statistical difference between the groups (p=0.01). After 3 months of treatment, there were no statistically significant improvements in the resting pain scores for patients receiving calcitonin (SMD=0.17, 95% CI=−1.46 to 1.12) compared with the control group. The chi-square test for heterogeneity was relatively significant for the RE pooled result (I 2 =84%, p=0.01). One study reported results for up to 1 year [16] , with no statistically significant difference in pain scores between the calcitonin group and the control group (SMD=−0.42, 95% CI=−0.84 to 0.00, p=0.05).
Sensitivity analysis, based on the imputing of SDs into the studies where means were provided (but no SD), was not done as the SD had to be imputed for both of the included trials. Of the two included studies, one used synthetic eel calcitonin [77] and the other synthetic salmon calcitonin [16] ; with limited data provided, sensitivity analyses related to calcitonin derivative could not be done.
Chronic pain with mobility Four of the five studies measured chronic back pain with activity [16, [79] [80] [81] ; RE pooled results of the population at baseline revealed a homogeneous sample (I 2 =0%, p=0.44) with no statistical difference between groups (p=0.29). With the exception of the pooled results at 6 months, there were no significant improvements in pain scores. At 6 months, there appeared to be a significant difference in pain scores for the calcitonin group (SMD=−0.49, 95% CI=−0.85 to −0.13, p=0.008, I
2 =0%) compared with the control group (forest plot of the results presented in Fig. 4) .
The only comparisons demonstrating heterogeneity (I 2 = 86%, p<0.0009) in their RE pooled results was at 3 months. As SD for both of the studies reporting results at 3 months were not provided (and were therefore imputed) [16, 81] , sensitivity analysis was not done. Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 1 (P = 0.68); I² = 0% Test for overall effect: Z = 2.65 (P = 0.008)
Heterogeneity: Tau² = 0.11; Chi² = 22.66, df = 11 (P = 0.02); I² = 51% Test for overall effect: Z = 1.02 (P = 0.31) 
Withdrawals
Of the 13 included studies, six reported 16 patient withdrawals; nine (7.2%) withdrawals were from the calcitonin group (eight due to side effects and one with no reason provided) and seven (5.3%) from the control group (one related to side effects, five due to lack of efficacy, and one with no reason provided). The pooled RE model provided a RR of 1.26 (95% CI=0.46 to 3.43), and the calculated number needed to treat to prevent one additional withdrawal (NNTH) for all cause withdrawal was 73. Specifically, two studies, both examining chronic pain, reported two withdrawals from the IN calcitonin group (3.9%) and none from the control group, giving a RR of 3.07 (95% CI=0.34 to 27.79, p=0.32). Four studies using injectable calcitonin (IM or SQ), two of which reported on acute pain and two on chronic pain, reported six (11.1%) withdrawals from the calcitonin group and four (6.8%) from the control group; the RE pooled analysis showed a RR of 1.49 (95% CI=0.40 to 5.61, p=0.55) and a calculated NNTH of 30. One study utilizing rectal suppository calcitonin reported one withdrawal (5%) from the treatment group and three (15%) withdrawals from the control group; this was not statistically significant (p=0.32; see Table 3 ).
Side effects
The 13 included studies reported 104 separate side effects; 85 were reported in the calcitonin group [the majority due to enteric disturbances (47%) and flushing (32%)] and 19 in the control group [mainly due to enteric disturbances (68%)]. The pooled RE model showed a RR of 3.09 (95% CI=1.80 to 5.32, p<0.0001) and a calculated NNTH of 12 (the number of patients who receive calcitonin that will lead to one additional patient experiencing a side effect, in comparison to the control group). Side effects were generally reported as mild, with the majority being either enteric disturbances (RR=2.58, 95% CI=1.10 to 6.04) or flushing (RR=6.91, 95% CI=2.47 to 19.36), both of which were statistically significant (see Table 4 ).
Concomitant analgesic use
We were not able to utilize statistical methods to assess concomitant analgesic use as there were not only substantial gaps in the data reported but also important differences in the reporting of results between studies. Seven studies reported analgesic use as an outcome of the study; this varied significantly from reporting the daily or weekly mean consumption of acetaminophen [16, 71, 73, 74, 77, 81] to converting the analgesic administered to equivalent milligrams of morphine ingested daily [76] . In five of the studies, concomitant analgesic use was not an outcome of interest and was therefore not reported on [17, 72, 75, 78, 79] ; in one of the studies, concomitant analgesia was not permitted [80] .
Discussion
Overall, the evidence presented in this review supports the use of calcitonin as an effective analgesic for the acute pain of recent OVCF in older adults. The included studies demonstrated a clear benefit with respect to pain relief. Pain was rated as severe by patients in both groups at baseline, suggesting that this diagnosis is important not only to health care providers but also to individual patients. By 1 week post-treatment, there were clinically (≥20/100 mm on the VAS) and statistically significantly differences in the pain scores of the calcitonin group compared with those in the control group. Various studies have investigated the minimum clinically significant change in patients' pain severity measured with a 10-cm VAS and found 1.3 cm as the cutoff [83, 84] . This, along with the finding that all studies of acute pain of OVCF reported statistically significant results for the analgesic efficacy of calcitonin, suggests that these results are not due to chance. Although not specifically evaluated in this review, earlier mobilization would be expected to reduce the incidence of other problems associated with immobility such as muscle atrophy and venous thromboembolism. Although used in clinical practice, the findings of this review do not support the use of calcitonin for chronic pain of more remote OVCFs. The subgroup analysis of analgesic efficacy with patients at rest did not demonstrate any clinical or statistical difference in pooled results from baseline through year 1. For the pooled analyses of patients while mobile, there was statistical significance only at 6 months in pain scores for the calcitonin group compared with the control group; regardless, we did not determine this to be of clinical importance.
We postulated that the route of administration may have in part explained the heterogeneity of the results. Unfortunately, due to so few studies included in the individual analyses, it was not possible to do subgroup analysis based on route of calcitonin administration. For example, either there was only one study included per route of administration or the calcitonin was given in different doses (IM 50 vs. 100 IU), making it impossible to compare the results. The included studies used different routes of administration and various doses of calcitonin; therefore, insufficient data were available to evaluate a dose-response effect of calcitonin. However, it appeared that the trials employing IM or SQ injections showed the greatest difference in pain scores between calcitonin and control groups. This may be in part due to the greater bioavailability of the drug when administered via the IM route. The bioavailability of IN calcitonin is only about 25% of the administered dose as compared with the injectable preparation, which is 70% bioavailable [85] . Clinically, given the age and comorbidities of the affected patients, it is clearly easier to administer the agent via the IN route than the IM route, adjusting the dose accordingly to reflect bioavailability of the drug. The withdrawal rate for any cause was low and was seen in slightly more patients in the treatment group than placebo; this was not a statistically significant finding. The NNT to prevent one additional withdrawal (for all cause withdrawal) with calcitonin was high at 73. There were more withdrawals in the acute pain group than in the chronic pain group; this is not surprising as, presumably, the patients in these trials would have been suffering from acute, extreme pain and almost all of the withdrawals were due to lack of perceived efficacy (not side effects).
Overall, this treatment approach seems to be safe. There were side effects reported in these trials; however, they were generally described as mild and self-limiting. There were statistically significant increases in gastrointestinal/ enteric disturbances and flushing compared with placebo. These side effects may in part be related to the route of administration as both were noticed predominantly in the studies where injectable calcitonin was utilized. There were also more side effects in the chronic pain group; given the much longer duration of these studies (1 year vs. 4 weeks), this was expected.
Overall completeness and applicability of evidence There are several methodological issues that would limit the generalizability (external validity) of these results, although the overall findings seem to apply to all patients. Due to the small number of trials included in this meta-analysis and the overall small number of patients upon which these results are based, no firm conclusions regarding the subgroups (other than the acute pain group) can be made.
Four of the five studies included in the acute pain analysis were conducted in a hospital setting where patient presentations may be more severe than in an ambulatory office or clinic setting. Consequently, the results pertaining to the use of calcitonin for acute OVCF need confirmation in the community setting. In addition, the overall findings may only be generalized to people who have OVCF and limited comorbid disease as described in the exclusion criteria of the studies. People with secondary osteoporosis or those receiving concomitant osteoporosis treatments were not studied. Moreover, analyses adjusting for confounding factors or population stratification were not performed due to insufficient data.
Quality of the evidence
The methodological quality of the individual included studies was assessed according to the "risk of bias approach" of the Cochrane Collaboration [25] . Information related to acceptable randomization, allocation concealment, and blinded outcome assessments varied significantly and were not adequately reported in most of the studies. In fact, only three studies addressed all six of the formal quality criteria. Although the authors of the 13 included studies all claimed that their study design was a randomized controlled trial, an appropriate method of randomization and concealment of treatment allocation was determined in only three of the studies after contact with the study author (all three studies were by the same author). Perhaps, if all study authors had been successfully contacted, this would have been clarified for all of the studies.
None of the studies followed the CONSORT reporting guidelines [86] . Consequently, there were no reports on numbers of patients excluded from the studies prior to randomization and there was no information on how those included differed from those who were excluded. We do not know how this would influence the estimate of effect; however, since the effect in the acute pain subgroup is very robust (note the narrow confidence intervals), we are reasonably confident of the results.
Although all studies reported data on side effects and withdrawals, none reported on compliance with the chosen treatment. Compliance can be a confounding factor when studying the effectiveness of any treatment; when the compliance is generally low (usually a matter of selfselection), it is difficult to be certain of the real effectiveness of the treatment.
Potential biases in the review process
The two review authors who assessed the methodological quality were not blinded for authors, journal, or institution. The potential bias caused by the non-blinded quality assessment was expected to be low as neither review author had a conflict of interest. Specifically, the review authors did not have any (financial or other) interest in positive or negative results. Furthermore, we searched the gray literature extensively for eligible trials, presented the search strategy and the inclusion criteria list, and all of the final results of the assessment so that readers can make their own determinations of the results and our conclusions.
There is a possibility of publication bias or study selection bias in this meta-analysis. For example, by missing unpub-lished negative trials, we may be overestimating the treatment effect of calcitonin. However, a comprehensive search of the published literature for potentially relevant studies was conducted using a systematic strategy to avoid bias. This was followed by attempts to contact corresponding and first authors as we recognize that unpublished or negative trials may exist. We did identify three relevant trials that were not included in the metaanalysis; however, despite concerted efforts to communicate with the authors to clarify methodological issues and obtain additional data, we were unable to locate primary study authors and therefore could not include them in the analysis.
Authors' conclusions
Implications for practice
OVCFs are a significant problem for which many older adults seek medical attention, some of whom are subsequently admitted to hospital. The evidence from this metaanalysis suggests that calcitonin should be considered as an adjunctive analgesic for acute pain associated with recent OVCF. When comparing the route of calcitonin administration, injections may provide more rapid analgesic effect, reducing the time to return to mobilization; however, this observation requires confirmation. Despite a small statistically significant improvement in pain scores at 6 months, there is insufficient evidence to support the use of calcitonin for chronic back pain attributed to remote OVCFs.
Implications for research
Further RCTs, with adequate sample sizes, are necessary to elucidate the analgesic properties of calcitonin and the significance of side effects. Future research should focus on effective dose ranges and their duration of response and the long-term efficacy of calcitonin, particularly in post-menopausal women in whom the majority of OVCF fractures are seen. A cost analysis of calcitonin therapy vs. conventional therapy (e.g., narcotics, newer COX-2-inhibitors, etc.) taking into account health-related quality of life issues, length of time to mobilization, length of hospital stay, and patient preference all need careful consideration when choosing one treatment over another. Finally, trials comparing calcitonin to other analgesics or in combination with other analgesics are needed. Considering the complexity of pain control, it may not be reasonable to look for a single drug to control the severe pain of vertebral compression fractures.
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